Peptide and Recombinant Immunotherapy

Immunology and Allergy Clinics of North America

Volumn 31, Issue 2, 2011, Pages 377-389

  Larché, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Blocking Ab; Epitope; Peptide; Recombinant protein; Regulation; T cell

Indexed keywords

ALLERVAXCAT; B LYMPHOCYTE ANTIBODY; CHIMERIC PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; DER P 1 PEPTIDE; FC RECEPTOR IIB; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; INTERLEUKIN 13; INTERLEUKIN 5; PEPTIDE VACCINE; PHL P1 ALLERGEN; PHL P2 ALLERGEN; PHL P5A ALLERGEN; PHL P5B ALLERGEN; PHL P6 ALLERGEN; PLACEBO; POLYPEPTIDE; RECOMBINANT ALLERGEN; RECOMBINANT BET V 1A ALLERGEN; TOLEROMUNE CAT; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ALLERGIC ASTHMA; ALLERGIC DISEASE; ANTIBODY DETECTION; ANTIBODY TITER; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOREACTIVITY; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN CROSS LINKING; PROTEIN FOLDING; REVIEW; RHINOCONJUNCTIVITIS; VIRUS LIKE AGENT;

ALLERGENS; ANIMALS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; HUMANS; HYPERSENSITIVITY; PEPTIDES; RECOMBINANT PROTEINS;

EID: 79955403741     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2011.03.008     Document Type: Review

References (74)

1. Durham S.R., Walker S.M., Varga E.M., et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999, 341(7):468-475.
2. Bousquet J., Lockey R., Malling H.J., et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998, 81(5 Pt 1):401-405.
3. Calderon M.A., Casale T.B., Togias A., et al. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011, 127(1):30-38.
4. Dahl R., Kapp A., Colombo G., et al. Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol 2008, 121(2):512-518.
5. Durham S.R. SQ-standardised grass tablet sublingual immunotherapy: persistent clinical benefit and progressive immunological changes during three years treatment. Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M 2009, 96:121-127.
6. Wilson D.R., Lima M.T., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005, 60(1):4-12.
7. Abramson M., Puy R., Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 1999, 54(10):1022-1041.
8. Jacobsen L., Niggemann B., Dreborg S., et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62(8):943-948.
9. Ferreira F., Rohlfs A., Hoffmann-Sommergruber K., et al. Modulation of IgE-binding properties of tree pollen allergens by site-directed mutagenesis. Adv Exp Med Biol 1996, 409:127-135.
10. Okada T., Swoboda I., Bhalla P.L., et al. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett 1998, 434(3):255-260.
11. Swoboda I., De Weerd N., Bhalla P.L., et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur J Immunol 2002, 32(1):270-280.
12. Swoboda I., Bugajska-Schretter A., Linhart B., et al. A recombinant hypoallergenic parvalbumin mutant for immunotherapy of IgE-mediated fish allergy. J Immunol 2007, 178(10):6290-6296.
13. Burks A.W., King N., Bannon G.A. Modification of a major peanut allergen leads to loss of IgE binding. Int Arch Allergy Immunol 1999, 118(2-4):313-314.
14. Rabjohn P., West C.M., Connaughton C., et al. Modification of peanut allergen Ara h 3: effects on IgE binding and T cell stimulation. Int Arch Allergy Immunol 2002, 128(1):15-23.
15. Stanley J.S., King N., Burks A.W., et al. Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. Arch Biochem Biophys 1997, 342(2):244-253.
16. Drew A.C., Eusebius N.P., Kenins L., et al. Hypoallergenic variants of the major latex allergen Hev b 6.01 retaining human T lymphocyte reactivity. J Immunol 2004, 173(9):5872-5879.
17. Bolhaar S.T., Zuidmeer L., Ma Y., et al. A mutant of the major apple allergen, Mal d 1, demonstrating hypo-allergenicity in the target organ by double-blind placebo-controlled food challenge. Clin Exp Allergy 2005, 35(12):1638-1644.
18. Ferreira F., Ebner C., Kramer B., et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 1998, 12(2):231-242.
19. Kussebi F., Karamloo F., Rhyner C., et al. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005, 115(2):323-329.
20. King T.P., Jim S.Y., Monsalve R.I., et al. Recombinant allergens with reduced allergenicity but retaining immunogenicity of the natural allergens: hybrids of yellow jacket and paper wasp venom allergen antigen 5s. J Immunol 2001, 166(10):6057-6065.
21. Hirahara K., Tatsuta T., Takatori T., et al. Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J Allergy Clin Immunol 2001, 108(1):94-100.
22. Karamloo F., Schmid-Grendelmeier P., Kussebi F., et al. Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes. Eur J Immunol 2005, 35(11):3268-3276.
23. Westritschnig K., Linhart B., Focke-Tejkl M., et al. A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin. J Immunol 2007, 179(11):7624-7634.
24. Campana R., Vrtala S., Maderegger B., et al. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly. J Allergy Clin Immunol 2010, 126(5):1024-1031. 1031.
25. Niederberger V., Horak F., Vrtala S., et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 2004, 101(Suppl 2):14677-14682.
26. Fellrath J.M., Kettner A., Dufour N., et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003, 111(4):854-861.
27. Worm M., Lee H.H., Kleine-Tebbe J., et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol 2011, 127(1):89-97.
28. Alexander C., Tarzi M., Larche M., et al. The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005, 60(10):1269-1274.
29. Alexander C., Ying S., Kay B., et al. Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25; CD4 interferon-gamma T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy 2005, 35(1):52-58.
30. Oldfield W.L., Kay A.B., Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001, 167(3):1734-1739.
31. Oldfield W.L., Larche M., Kay A.B. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002, 360(9326):47-53.
32. Arquint O., Helbling A., Crameri R., et al. Reduced in vivo allergenicity of Bet v 1d isoform, a natural component of birch pollen. J Allergy Clin Immunol 1999, 104(6):1239-1243.
33. Hiller R., Laffer S., Harwanegg C., et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. FASEB J 2002, 16(3):414-416.
34. Schmid-Grendelmeier P., Crameri R. Recombinant allergens for skin testing. Int Arch Allergy Immunol 2001, 125(2):96-111.
35. Jutel M., Jaeger L., Suck R., et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005, 116(3):608-613.
36. Pauli G., Larsen T.H., Rak S., et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008, 122(5):951-960.
37. Vrtala S., Hirtenlehner K., Susani M., et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1. FASEB J 2001, 15(11):2045-2047.
38. Vrtala S., Hirtenlehner K., Vangelista L., et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy. J Clin Invest 1997, 99(7):1673-1681.
39. Hage-Hamsten M., Kronqvist M., Zetterstrom O., et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1: results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 1999, 104(5):969-977.
40. Vrtala S., Akdis C.A., Budak F., et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 2000, 165(11):6653-6659.
41. Campana R., Vrtala S., Maderegger B., et al. Altered IgE epitope presentation: a model for hypoallergenic activity revealed for Bet v. 1 trimer. Mol Immunol 2011, 48(4):431-441.
42. Egger C., Horak F., Vrtala S., et al. Nasal application of rBet v 1 or non-IgE-reactive T-cell epitope-containing rBet v 1 fragments has different effects on systemic allergen-specific antibody responses. J Allergy Clin Immunol 2010, 126(6):1312-1315.
43. Pree I., Shamji M.H., Kimber I., et al. Inhibition of CD23-dependent facilitated allergen binding to B cells following vaccination with genetically modified hypoallergenic Bet v 1 molecules. Clin Exp Allergy 2010, 40(9):1346-1352.
44. Reisinger J., Horak F., Pauli G., et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005, 116(2):347-354.
45. Niederberger V., Reisinger J., Valent P., et al. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol 2007, 119(4):1013-1016.
46. Gafvelin G., Thunberg S., Kronqvist M., et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005, 138(1):59-66.
47. Purohit A., Niederberger V., Kronqvist M., et al. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008, 38(9):1514-1525.
48. Kundig T.M., Senti G., Schnetzler G., et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006, 117(6):1470-1476.
49. Senti G., Johansen P., Haug S., et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy 2009, 39(4):562-570.
50. Djurup R., Malling H.J. High IgG4 antibody level is associated with failure of immunotherapy with inhalant allergens. Clin Allergy 1987, 17(5):459-468.
51. Wachholz P.A., Soni N.K., Till S.J., et al. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003, 112(5):915-922.
52. Shamji M.H., Wilcock L.K., Wachholz P.A., et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods 2006, 317(1-2):71-79.
53. Focke M., Linhart B., Hartl A., et al. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy 2004, 34(10):1525-1533.
54. Edlmayr J., Niespodziana K., Linhart B., et al. A combination vaccine for allergy and rhinovirus infections based on rhinovirus-derived surface protein VP1 and a nonallergenic peptide of the major timothy grass pollen allergen Phl p 1. J Immunol 2009, 182(10):6298-6306.
55. Campana R., Mothes N., Rauter I., et al. Non-IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments. J Allergy Clin Immunol 2008, 121(2):528-530.
56. Kepley C.L., Taghavi S., Mackay G., et al. Co-aggregation of FcgammaRII with FcepsilonRI on human mast cells inhibits antigen-induced secretion and involves SHIP-Grb2-Dok complexes. J Biol Chem 2004, 279(34):35139-35149.
57. Zhang K., Kepley C.L., Terada T., et al. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol 2004, 114(2):321-327.
58. Zhang K., Zhu D., Kepley C., et al. Chimeric human fcgamma-allergen fusion proteins in the prevention of allergy. Immunol Allergy Clin North Am 2007, 27(1):93-103.
59. Zhu D., Kepley C.L., Zhang K., et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005, 11(4):446-449.
60. Terada T., Zhang K., Belperio J., et al. A chimeric human-cat Fcgamma-Fel d1 fusion protein inhibits systemic, pulmonary, and cutaneous allergic reactivity to intratracheal challenge in mice sensitized to Fel d1, the major cat allergen. Clin Immunol 2006, 120(1):45-56.
61. Norman P.S., Ohman J.L., Long A.A., et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996, 154(6 Pt 1):1623-1628.
62. Marcotte G.V., Braun C.M., Norman P.S., et al. Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998, 101(4 Pt 1):506-513.
63. Pene J., Desroches A., Paradis L., et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998, 102(4 Pt 1):571-578.
64. Maguire P., Nicodemus C., Robinson D., et al. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999, 93(3):222-231.
65. Simons F.E., Imada M., Li Y., et al. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996, 8(12):1937-1945.
66. Haselden B.M., Kay A.B., Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999, 189(12):1885-1894.
67. Smith T.R., Alexander C., Kay A.B., et al. Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25 T cells: a double-blind placebo-controlled study. Allergy 2004, 59(10):1097-1101.
68. Verhoef A., Alexander C., Kay A.B., et al. T cell epitope immunotherapy induces a CD4(+) T cell population with regulatory activity. PLoS Med 2005, 2(3):e78.
69. Campbell J.D., Buckland K.F., McMillan S.J., et al. Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 2009, 206(7):1535-1547.
70. Larche M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007, 119(4):906-909.
71. Carballido J.M., Carballido-Perrig N., Kagi M.K., et al. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol 1993, 150(8 Pt 1):3582-3591.
72. Muller U., Akdis C.A., Fricker M., et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998, 101(6 Pt 1):747-754.
73. Texier C., Pouvelle S., Busson M., et al. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000, 164(6):3177-3184.
74. Tarzi M., Klunker S., Texier C., et al. Induction of interleukin-10 and suppressor of cytokine signaling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006, 36(4):465-474.